“互联网+医疗健康”背景下零售药店执业药师审方的风险防范与对策  

Risk Prevention and Countermeasures in the Process of Prescription Reviewed by Licensed Pharmacists in Retail Pharmacies Under the Background of″Internet+Medical Health″

作　　者：蒋皓 束雅春 胡晓翔 祝红宇 蒋永兆 JIANG Hao;SHU Yachun;HU Xiaoxiang;ZHU Hongyu;JIANG Yongzhao(Nanjing Branch of Jiangsu Suncadia Industrial Co.,Ltd.,Nanjing,Jiangsu,China 210000;Jiangsu Hengrui Medicine Co.,Ltd.,Lianyungang,Jiangsu,China 222000;Affiliated Hospital of Nanjing University of Chinese Medicine•Jiangsu Provincial Hospital of Chinese Medicine,Nanjing,Jiangsu,China 210000;Nanjing Municipal Health Commission,Nanjing,Jiangsu,China 210019;Nanjing Administration of Market Regulation,Nanjing,Jiangsu,China 210000)

机构地区：[1]江苏盛迪亚实业有限公司南京分公司,江苏南京210000 [2]江苏恒瑞医药股份有限公司,江苏连云港222000 [3]南京中医药大学附属医院·江苏省中医院,江苏南京210000 [4]江苏省南京市卫生健康委员会,江苏南京210019 [5]江苏省南京市市场监督管理局,江苏南京210000

出　　处：《中国药业》2024年第1期10-14,共5页China Pharmaceuticals

摘　　要：目的 探讨“互联网+医疗健康”背景下零售药店执业药师审方的风险防范措施。方法 结合文献与现场调研,以2021年江苏省南京市市场监督管理局药品零售监管相关要素(如执业药师审方错误、执业药师不在岗销售处方等)为例,梳理执业药师注册情况、审方依据、线上/线下审方流程,分析执业药师在药品零售环节处方审核过程中的风险点,并提出风险防范措施与对策。结果与结论 风险点集中于执业药师审方能力不足,市场需求量与注册率相矛盾,专业技术水平发展滞后。审方流程中,缺乏处方合规性审核手段,互联网医院或第三方购药平台处方的开具和审核缺乏监管制度,缺乏与实体医疗机构合作的审方机制,易受消费者和企业利益驱动影响。建议提升药师执业能力,探索多元化管理模式,实现处方流转共享机制,构建区域联合审方中心,完善相关法律法规,拓宽基层医疗机构的资源共享范围,由多方敦促形成共治格局,保障群众用药安全。Objective To investigate the prevention measures for the risk in the process of prescription reviewed by licensed pharmacists in retail pharmacies under the background of″Internet+medical health″.Methods Based on literature review and on-site research,the relevant elements of drug retail supervision by the Nanjing Administration of Market Regulation in 2021(such as errors in prescription reviewed by licensed pharmacists,sales of prescriptions by licensed pharmacists who are not on duty,etc.)were taken as examples to sort out the registration situation of licensed pharmacists,review basis,online/offline review process,the risk points of licensed pharmacists in the prescription review process of drug retail were analyzed,and the risk prevention measures and countermeasures were put forward.Results and Conclusion The risk points were concentrated in the insufficient review ability of licensed pharmacists,the contradiction between market demand and registration rate,and the lagging development of the professional technical level.In the review process,there was a lack of means for prescription compliance review,inadequate regulatory mechanisms of prescription issuance and review in internet hospitals or third-party drug purchasing platforms,and a lack of review mechanisms in cooperation with off-line medical institutions,which were easily influenced by consumer and corporate interests.It is recommended to enhance the professional ability of pharmacists,explore a diversified management model,realize a shared mechanism for prescription circulation,construct the regional center for joint prescription review,improve relevant laws and regulations,broaden resource-sharing channels for primary health care institutions,and promote the formation of a pattern of common governance through multi-party efforts to ensure the safety of medication for the public.

关 键 词：“互联网+医疗健康” 执业药师 处方药 处方审核 

分 类 号：R95[医药卫生—药学]